Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

NCT04030429 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
40
Enrollment
OTHER
Sponsor class

Stopped Patients were recruited during screen phase but fewer patients met criteria.

Conditions

Interventions

Sponsor

National Cheng-Kung University Hospital

Collaborators